Upfront Immunotherapy for Metastatic Kidney Cancer
0 Visningar
• 06/26/23
0
0
Bädda in
administrator
Prenumeranter
Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna